A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children.

janelia7_blocks-janelia7_biblio_header | block

Lancet. 2002 Nov 9;360(9344):1468-75. doi: 10.1016/S0140-6736(02)11474-7

Hobbs MR, Udhayakumar V, Levesque MC, Booth J, Roberts JM, Tkachuk AN, Pole A, Coon H, Kariuki S, Nahlen BL, Mwaikambo ED, Lal AL, Granger DL, Anstey NM, Weinberg JB

Note: Research in this publication was not performed at Janelia.

janelia7_blocks-janelia7_biblio_abstract | block

Abstract

Nitric oxide (NO) is a mediator of immunity to malaria, and genetic polymorphisms in the promoter of the inducible NO synthase gene (NOS2) could modulate production of NO. We postulated that NOS2 promoter polymorphisms would affect resistance to severe malaria.

PMID: 12433515 [PubMed - indexed for MEDLINE]

node:body | entity_field

Main Menu (Mobile)- Block

Main Menu - Block

A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children.

Note: Research in this publication was not performed at Janelia.

Abstract

PMID: 12433515 [PubMed - indexed for MEDLINE]

Janelia Authors